"Teva's oral treatment for multiple sclerosis, Laquinimod, was granted "fast track" designation by the US Food and Drug Administration (FDA). Fast Track designation can potentially facilitate development and expedite the review process. According to Teva, this may allow the drug to enter the market as soon as late 2011."